| abstract |
The present invention relates to the use of sodium borates alone as an active ingredient to prevent and/or treat fatty liver. In addition, sodium borates alone are within the scope of the invention to reduce the expression levels of AADIPOR2, PRKAG2, IRS1, PIK3R1, NFKB1, MAP3K11, BID, CYCS, BAX, CASP3 and TGFB1 genes in the non-alcoholic fatty liver pathway and thereby to prevent and/or treat fatty liver by inhibiting the functioning of the non-alcoholic fatty liver pathway. |